Kodak Oncology Imaging Film System Wins R&D 100 Award

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 10
Volume 6
Issue 10

ROCHESTER, NY-The Eastman Kodak Company has been selected to receive the 1997 R&D 100 Award for its development of the Kodak EC-L film system for oncology imaging. The award-winning system provides high-contrast images for use in monitoring radiation treatment of cancer patients.

ROCHESTER, NY—The Eastman Kodak Company has been selected to receive the 1997 R&D 100 Award for its development of the Kodak EC-L film system for oncology imaging. The award-winning system provides high-contrast images for use in monitoring radiation treatment of cancer patients.

The award has been sponsored by R&D Magazine for 35 years. Sometimes referred to as “the Nobel Prize of applied research,” the R&D 100 Award pays tribute to products and processes that have revolutionized their particular field and impacted the way people live. Past winners, for example, have included the automated teller machine, the fax machine, the digital wristwatch, and antilock brakes.

The EC-L film system has advanced the precision of radiation therapy by allowing oncologists to verify treatment of tumors with increased ease and accuracy, the company said. The complete Kodak EC-L film system consists of Kodak EC-L film and Kodak EC-L oncology cassettes.

The EC-L film system combines fluorescent intensifying screens and a low-speed, very-fine-grain, high-contrast film emulsion. According to Kodak, the resulting images have significantly higher contrast—approximately four times that of conventional film systems—and show more anatomic detail (see images in the figure ).

The system was developed by three scientists in Kodak’s Health Imaging Division (see photograph ): Arthur G. Haus, director of medical physics;

Kenneth E. Huff, senior research physicist; and Robert E. Dickerson, senior technical associate for the Film Development Laboratory.

Recent Videos
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
Related Content